MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FANTOZZI, R.
Right arrow Articles by BLUME, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FANTOZZI, R.
Right arrow Articles by BLUME, A. J.

Molecular Pharmacology, Vol 20, 8-15, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

Irreversible Inactivation of the Opiate Receptors in the Neuroblastoma x Glioma Hybrid NG108-15 by Chlornaltrexamine

ROBERT FANTOZZI 1, DEBRA MULLIKIN-KILPATRICK 1, and ARTHUR J. BLUME 1

1 Department of Physiological Chemistry and Pharmacology, Roche Institute of Molecular Biology, Nutley, New Jersey 07110

Chlornaltrexamine irreversibly inactivates opiate receptors in intact NG108-15 cells in a concentration- and time-dependent fashion. This inactivation is seen as a loss in the number of receptors per cell (decrease in Bmax), and is quantitatively the same whether based on the number of specific binding sites for the agonist opioid peptide [D-Ala2-Met5] enkephalinamide or those for the opiate antagonist naltrexone. Inactivation appears to require direct interaction of chlornaltrexamine with these receptors as naltrexone and [D-Ala2-Met5]enkephalinamide protect against the irreversible effects of chlornaltrexamine. Furthermore, treatment with chlornaltrexamine does not decrease muscarinic or prostaglandin receptors or diazepam binding sites in NG108-15. In intact NG108-15 cells, the opioid peptide [D-Ala2-Met5]enkephalinamide can inhibit 80 ± 10% of the accumulation of cyclic AMP that is stimulated by prostaglandin E1. In control cells, the action of this peptide is cooperative and the half-maximum effect (Kinh) occurs with 3.3 nM peptide. Under identical conditions, the half-maximum receptor occupancy by the peptide (KD) is 23 nM. After the opiate receptor number is significantly decreased by previous incubation with chlornaltrexamine, both the maximal effects of prostaglandin E1, as stimulator of cyclic AMP accumulation, and the opioid peptide, as inhibitor of this accumulation, are maintained. In the case where the receptor number has been reduced by 95%, although there is a small change (le3-fold) in the KD and Kinh values for this opioid peptide, there is no significant change in the KD/Kinh ratio which remains sime7. These results indicate that the high density of opiate receptors which exist in intact NG108-15 cells is not necessary for the maximum inhibitory effect of this enkephalinamide on adenylate cyclase. In addition, the mode of action of this peptide also appears to be relatively independent of the density of the opiate receptors in these cells.

Submitted on November 10, 1980
Accepted on February 26, 1981




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
P. A. Zaki, D. E. Keith Jr., G. A. Brine, F. I. Carroll, and C. J. Evans
Ligand-Induced Changes in Surface {micro}-Opioid Receptor Number: Relationship to G Protein Activation?
J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1127 - 1134.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. P. McLaughlin, K. P. Hill, Q. Jiang, A. Sebastian, S. Archer, and J. M. Bidlack
Nitrocinnamoyl and Chlorocinnamoyl Derivatives of Dihydrocodeinone: In Vivo and In Vitro Characterization of µ-Selective Agonist and Antagonist Activity
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 304 - 311.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Alt, A. Mansour, H. Akil, F. Medzihradsky, J. R. Traynor, and J. H. Woods
Stimulation of Guanosine-5'-O-(3-[35S]Thio)Triphosphate Binding by Endogenous Opioids Acting at a Cloned Mu Receptor
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 282 - 288.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
W. Jin, G. W. Terman, and C. Chavkin
Kappa Opioid Receptor Tolerance in the Guinea Pig Hippocampus
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 123 - 128.
[Abstract] [Full Text]


Home page
ScienceHome page
M. Charness, A. Gordon, and I Diamond
Ethanol modulation of opiate receptors in cultured neural cells
Science, December 16, 1983; 222(4629): 1246 - 1248.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
P.-Y. Law, O. M.-E. Kouhen, J. Solberg, W. Wang, L. J. Erickson, and H. H. Loh
Deltorphin II-induced Rapid Desensitization of delta -Opioid Receptor Requires Both Phosphorylation and Internalization of the Receptor
J. Biol. Chem., October 6, 2000; 275(41): 32057 - 32065.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. M.-E. Kouhen, G. Wang, J. Solberg, L. J. Erickson, P.-Y. Law, and H. H. Loh
Hierarchical Phosphorylation of delta -Opioid Receptor Regulates Agonist-induced Receptor Desensitization and Internalization
J. Biol. Chem., November 17, 2000; 275(47): 36659 - 36664.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics